Host: Rabbit
Target Protein: Integrin alpha V/CD51
Immunogen Range: 51-150/1048
Clonality: Polyclonal
Isotype: IgG
Entrez Gene: 3685
Swiss Prot: P06756
Source: KLH conjugated synthetic peptide derived from human Integrin alpha V
Purification: Purified by Protein A.
Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
Size: 100ul
Concentration: 1ug/ul
Applications:
WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
Predicted Molecular Weight: 95/113
Cross Reactive Species:
Human
Mouse
Predicted Cross Reactive Species:
Rat
Dog
Cow
Pig
Horse
Chicken
For research use only. Not intended for diagnostic or therapeutic use.
- Ulmasov, Barbara, et al. "Inhibitors of RGD-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice." CMGH Cellular and Molecular Gastroenterology and Hepatology (2016).Read more>>
- Agarwal, Shailesh, et al. "Analysis of bone‐cartilage‐stromal progenitor populations in trauma induced and genetic models of heterotopic ossification." STEM CELLS (2016).Read more>>
- Ulmasov et al. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. (2016) Cell.Mol.Gastroenterol.Hepatol. 2:499-518Read more>>
- Agarwal et al. Analysis of Bone-Cartilage-Stromal Progenitor Populations in Trauma Induced and Genetic Models of Heterotopic Ossification. (2016) Stem.Cells. 34:1692-701Read more>>
- Sidorenko Valeria. et al. Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy. SCI REP-UK. 2024 Jul;14(1):1-16Read more>>
A549 cell lysates probed with Integrin alpha V/CD51 Polyclonal Antibody, Unconjugated (bs-2250R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human Siha cell lysates; Lane 2: Human Hela cell lysates; Lane 3: Human HepG2 cell lysates; Lane 4: Human U251 cell lysates ; Lane 5: Human MCF-7 cell lysates probed with Integrin alpha V/CD51 Polyclonal Antibody, Unconjugated (bs-2250R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human A549 cell lysates; Lane 2: Human MCF-7 cell lysates; Lane 3: Human Huvec cell lysates probed with Integrin alpha V/CD51 Polyclonal Antibody, Unconjugated (bs-2250R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
U-2OS cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (CD51) polyclonal Antibody, Unconjugated (bs-2250R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Paraformaldehyde-fixed, paraffin embedded (rat kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Integrin alpha V/CD51) Polyclonal Antibody, Unconjugated (bs-2250R) at 1:500 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human kidney); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Integrin alpha V/CD51) Polyclonal Antibody, Unconjugated (bs-2250R) at 1:500 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.